Engineered Attenuated Salmonella typhimurium Expressing Neoantigen Has Anticancer Effects

Jungheun Hyun; Soyeong Jun; Hyeonseob Lim; Hyunjun Cho; Sung Hwan You; Sang Jun Ha; Jung Joon Min; Duhee Bang

doi:10.1021/acssynbio.1c00097

Engineered Attenuated Salmonella typhimurium Expressing Neoantigen Has Anticancer Effects

Jungheun Hyun, Soyeong Jun, Hyeonseob Lim, Hyunjun Cho, Sung Hwan You, Sang Jun Ha, Jung Joon Min, Duhee Bang

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Neoantigen vaccines are an immunotherapy strategy for treating cancer. The vaccine degrades quickly, so the strategy must include protection and precise targeting for immune cell stimulation. In this study, we engineered attenuated Salmonella typhimurium, which is highly infiltrative to tumors, to act as a carrier for Neoantigen peptide vaccine. Our system used a constitutive promoter vector, so that a single injection of Salmonella expressing Neoantigen could be used without requiring additional induction injections. In vivo experiments on bacteria-treated mice showed that Neoantigen expressed by the engineered carrier infiltrated tumors and resulted in suppressed tumor growth, higher survival rates and longer survival times, a relative increase of CD4 and CD8 T cells, and cytokine release. These results indicate that engineered Salmonella can be used as a carrier for Neoantigen immunotherapy.

Original language	English
Pages (from-to)	2478-2487
Number of pages	10
Journal	ACS Synthetic Biology
Volume	10
Issue number	10
DOIs	https://doi.org/10.1021/acssynbio.1c00097
Publication status	Published - 2021 Oct 15

Bibliographical note

Funding Information:
This research was supported by (i) the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (NRF-2018M3A9H3024850); (ii) the Midcareer Researcher Program (NRF-2021R1A2C2094264) through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT and Future Planning; (iii) Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea [Grant Number: HI14C1277(HR14C0003)]; (iv) the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2019M3A9B6065221).

Publisher Copyright:
© 2021 American Chemical Society.

All Science Journal Classification (ASJC) codes

Biomedical Engineering
Biochemistry, Genetics and Molecular Biology (miscellaneous)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/acssynbio.1c00097

Cite this

@article{ae0fd055cdd94eb2b7c4a1e93fcfb37b,

title = "Engineered Attenuated Salmonella typhimurium Expressing Neoantigen Has Anticancer Effects",

abstract = "Neoantigen vaccines are an immunotherapy strategy for treating cancer. The vaccine degrades quickly, so the strategy must include protection and precise targeting for immune cell stimulation. In this study, we engineered attenuated Salmonella typhimurium, which is highly infiltrative to tumors, to act as a carrier for Neoantigen peptide vaccine. Our system used a constitutive promoter vector, so that a single injection of Salmonella expressing Neoantigen could be used without requiring additional induction injections. In vivo experiments on bacteria-treated mice showed that Neoantigen expressed by the engineered carrier infiltrated tumors and resulted in suppressed tumor growth, higher survival rates and longer survival times, a relative increase of CD4 and CD8 T cells, and cytokine release. These results indicate that engineered Salmonella can be used as a carrier for Neoantigen immunotherapy.",

author = "Jungheun Hyun and Soyeong Jun and Hyeonseob Lim and Hyunjun Cho and You, {Sung Hwan} and Ha, {Sang Jun} and Min, {Jung Joon} and Duhee Bang",

note = "Funding Information: This research was supported by (i) the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (NRF-2018M3A9H3024850); (ii) the Midcareer Researcher Program (NRF-2021R1A2C2094264) through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT and Future Planning; (iii) Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea [Grant Number: HI14C1277(HR14C0003)]; (iv) the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2019M3A9B6065221). Publisher Copyright: {\textcopyright} 2021 American Chemical Society.",

year = "2021",

month = oct,

day = "15",

doi = "10.1021/acssynbio.1c00097",

language = "English",

volume = "10",

pages = "2478--2487",

journal = "ACS Synthetic Biology",

issn = "2161-5063",

publisher = "American Chemical Society",

number = "10",

}

TY - JOUR

T1 - Engineered Attenuated Salmonella typhimurium Expressing Neoantigen Has Anticancer Effects

AU - Hyun, Jungheun

AU - Jun, Soyeong

AU - Lim, Hyeonseob

AU - Cho, Hyunjun

AU - You, Sung Hwan

AU - Ha, Sang Jun

AU - Min, Jung Joon

AU - Bang, Duhee

N1 - Funding Information: This research was supported by (i) the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (NRF-2018M3A9H3024850); (ii) the Midcareer Researcher Program (NRF-2021R1A2C2094264) through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT and Future Planning; (iii) Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea [Grant Number: HI14C1277(HR14C0003)]; (iv) the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2019M3A9B6065221). Publisher Copyright: © 2021 American Chemical Society.

PY - 2021/10/15

Y1 - 2021/10/15

N2 - Neoantigen vaccines are an immunotherapy strategy for treating cancer. The vaccine degrades quickly, so the strategy must include protection and precise targeting for immune cell stimulation. In this study, we engineered attenuated Salmonella typhimurium, which is highly infiltrative to tumors, to act as a carrier for Neoantigen peptide vaccine. Our system used a constitutive promoter vector, so that a single injection of Salmonella expressing Neoantigen could be used without requiring additional induction injections. In vivo experiments on bacteria-treated mice showed that Neoantigen expressed by the engineered carrier infiltrated tumors and resulted in suppressed tumor growth, higher survival rates and longer survival times, a relative increase of CD4 and CD8 T cells, and cytokine release. These results indicate that engineered Salmonella can be used as a carrier for Neoantigen immunotherapy.

AB - Neoantigen vaccines are an immunotherapy strategy for treating cancer. The vaccine degrades quickly, so the strategy must include protection and precise targeting for immune cell stimulation. In this study, we engineered attenuated Salmonella typhimurium, which is highly infiltrative to tumors, to act as a carrier for Neoantigen peptide vaccine. Our system used a constitutive promoter vector, so that a single injection of Salmonella expressing Neoantigen could be used without requiring additional induction injections. In vivo experiments on bacteria-treated mice showed that Neoantigen expressed by the engineered carrier infiltrated tumors and resulted in suppressed tumor growth, higher survival rates and longer survival times, a relative increase of CD4 and CD8 T cells, and cytokine release. These results indicate that engineered Salmonella can be used as a carrier for Neoantigen immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85116264994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85116264994&partnerID=8YFLogxK

U2 - 10.1021/acssynbio.1c00097

DO - 10.1021/acssynbio.1c00097

M3 - Article

C2 - 34525796

AN - SCOPUS:85116264994

SN - 2161-5063

VL - 10

SP - 2478

EP - 2487

JO - ACS Synthetic Biology

JF - ACS Synthetic Biology

IS - 10

ER -

Engineered Attenuated Salmonella typhimurium Expressing Neoantigen Has Anticancer Effects

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this